SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pitt, B.
Right arrow Articles by Rajagopalan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitt, B.
Right arrow Articles by Rajagopalan, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease

Bertram Pitt

Division of Cardiology, The University of Michigan, USA, bpitt{at}umich.edu

Charles T Stier, Jr

Department of Pharmacology, New York Medical College, USA

Sanjay Rajagopalan

Division of Cardiology, The University of Michigan, USA

Mineralocorticoid receptor (MR) blockade is effective in reducing total mortality and the incidence of heart failure in patients with systolic left ventricular dysfunction (SLVD) associated with chronic heart failure or post myocardial infarction.

Pre-clinical and clinical studies in SLVD have shown that MR blockade reduces sudden cardiac death, left ventricular remodelling, left ventricular hypertrophy, endothelial dysfunction, autonomic imbalance, renal dysfunction and improves fibrinolysis.

While MR blockade promotes sodium excretion and the combination of an angiotensin-converting enzyme inhibitor and a MR blocker have been shown to be more effective than either alone in causing natriuresis, it is unlikely that their beneficial effects can be explained solely on this basis.

Aldosterone has been shown to have a number of adverse effects, including activation of other neurohumeral mediators, stimulation of active reactive oxygen species (ROS), activation of the NF-{kappa}β and AP-1 signalling pathways, vascular inflammation and fibrosis, myocardial hypertrophy, autonomic imbalance, and a decrease in fibrinolysis. MR blockade is, however, effective both in situations with and without an increase in serum aldosterone level, since the MR can be occupied and activated by cortisol as well as by aldosterone.

In view of these mechanisms, MR blockade may play an important role not only on SLVD, but also in essential hypertension with normal systolic function, diastolic heart failure, valvular heart disease, vascular stiffening with ageing, progression of renal disease, and diabetes mellitus. This hypothesis will, however, require further prospective evaluation.

Key Words: aldosterone • cortisol • systolic left ventricular dysfunction • heart failure • myocardial infarction

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 3, 164-168 (2003)
DOI: 10.3317/jraas.2003.025


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JNMHome page
S. Kasama, T. Toyama, H. Sumino, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure
J. Nucl. Med., December 1, 2007; 48(12): 1993 - 2000.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, G. Ertl, C. E. Angermann, and S. Stork
Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure
Circulation, April 3, 2007; 115(13): 1754 - 1761.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. S. Pitt and B. Pitt
Aldosterone, ion channels, and sudden death: another piece of the circle?
Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2176 - H2177.
[Full Text] [PDF]


Home page
J. Physiol.Home page
R. Perrier, S. Richard, Y. Sainte-Marie, B. C. Rossier, F. Jaisser, E. Hummler, and J.-P. Benitah
A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice
J. Physiol., November 15, 2005; 569(1): 153 - 162.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. M. Kuster, E. Kotlyar, M. K. Rude, D. A. Siwik, R. Liao, W. S. Colucci, and F. Sam
Mineralocorticoid Receptor Inhibition Ameliorates the Transition to Myocardial Failure and Decreases Oxidative Stress and Inflammation in Mice With Chronic Pressure Overload
Circulation, February 1, 2005; 111(4): 420 - 427.
[Abstract] [Full Text] [PDF]



Advertisement